Oct 27, 2026 earnings call — Mint FDA clearance and commercialization plan
Beta Bionics received FDA clearance for Mint and expects to fully commercialize it in the U.S. in Q1 of 2027.
Revenue $0.0B (est $0.0B) · EPS $-0.52 (est $-0.52)
Key quotes
"In September, we received FDA clearance for Mint, our transformative patch pump, which we expect to fully commercialize in the U.S. in Q1 of 2027."
"Our current expectation is to launch 3D Intelligence in the U.S. as iLet 3D and Mint 3D around mid-2027, subject to FDA clearance."
"A high 30s percentage of our new patients access iLet through the pharmacy channel, consistent with our expectations."
Analyst Q&A 13
3D simulator delay
Q (Matthew O'Brien · Piper Sandler): Analyst asked why 3D was delayed: was it validation testing, patient-specific testing, or human factors?
A: Management said the issue is with validating their simulator, not the algorithm or outcomes. They emphasized simulation is new for diabetes and the FDA guidance is still being interpreted, so they must prove the simulator's outputs are trustworthy.
"It's around the validation of our simulator, not the results of it, not the algorithm itself, not what we do, but just ensuring that we can trust the output of the simulator." — Sean Saint (CEO)
Mint shipment timing and 2027 sales
Q (Larry Biegelsen · Wells Fargo): When will first Mint commercial shipments occur, must 3D clear first, and how to model the ramp in 2027? Also, does management expect about $190 million sales next year?
A: They said first commercial shipments are expected in the first quarter and Mint can ship without 3D, though 3D would let them launch that feature on Mint sooner. For 2027 ramp, model it roughly linear from near 0 to average at least 1.5 million units; they expect to more than recover the 2026 deferral, adding at least $8.5 million into 2027.
"I think we've said probably all we're prepared to say on when the first commercial shipment will be, just in the first quarter here." — Sean Saint (CEO)
Fully closed loop design and type 2 trial timing
Q (Christopher Pasquale · Barclays): How does their fully closed loop approach differ from others and when will type 2 trial data be available?
A: They described fully closed loop as not requiring patient input and said they're making a simpler device aimed at both type 1 and type 2 users to broaden access. They will communicate the type 2 trial readout when they receive clearance, and they expect that clearance in the first half of next year.
"Said another way, we do believe that there's a huge cross-section of people that can benefit from an algorithm like that." — Sean Saint (CEO)
Production capacity and Mint gross margin
Q (Samuil-Hrabar Gatev · Leerink Partners): How much capacity exists to produce 1.5 million units, what milestones are needed before launch, and when will Mint become margin accretive?
A: They said they will start with a single manufacturing line that is near ready and are hiring to staff it for four shifts to run 24/7; expansion comes from replicating additional lines. They said Mint's gross margin will be dilutive in 2027 but expect within 3 years its gross margin to exceed the current patch pump incumbent due to design choices (durable plus lower-cost disposable).
"We're hiring for that line now, and we're, I'm not going to give an exact number, but meaningfully all the way through hiring a full 4 shifts for that line." — Sean Saint (CEO)
3D resubmission timing and simulator specifics
Q (Michael Polark · Barclays): Will the 3D resubmission allow clearance this year and is the simulator validation about a specific algorithm mode?
A: They said they will resubmit this year and there is a chance the FDA could pick up the file and clear it this year, but timing likely extends into next year. The FDA's questions were specific to the simulator validation process itself, not to any individual algorithm mode or the simulator outputs.
"On the second half of your question, it was -- the questions were very much specific to the simulator itself." — Sean Saint (CEO)
Pharmacy coverage and automation timeline
Q (Steven Lichtman · William Blair): What pharmacy coverage do you expect for Mint in 2027 and what about the timeline for fully automated manufacturing?
A: They expect roughly 40% of lives to be covered for Mint at launch, growing to around 50% by year-end 2027. On automation, they said additional lines are being constructed and they are working on more fully automated lines now but would not provide exact timelines.
"pharmacy coverage expectations for 2027 for Mint are at the time of launch, we expect roughly 40% of all lives in the country to be covered for Mint, growing to around 50% by the end of the year." — Stephen Feider (CFO)
Q3 pharmacy mix and Mint CapEx
Q (Jeffrey Cohen · Ladenburg Thalmann): What was Q3 pharmacy composition and is the $4M–$6M CapEx for one line and how will CapEx scale?
A: They said a high 30s percentage of new patient starts went through pharmacy in Q3. The near-term CapEx (low to mid-single-digit in Q4 and more in 2027) is for semi-automated and manual manufacturing across more than one line; fully automated line CapEx is a separate, later project.
"A high 30s percentage of our new patient starts went through pharmacy in the third quarter." — Stephen Feider (CFO)
Type 2 indication mechanics and forced FCL hypo risk
Q (Jeffrey Johnson · RW Baird): Will the type 2 indication use 3D or current algorithm, and does forced fully closed loop raise hypo risk for type 1?
A: They said they are not certain yet; at minimum the current algorithm mode could support type 2 indication, and they may apply simulation-cleared 3D to a broader indication after discussions with FDA. On forced fully closed loop, they do not expect it to increase hypos generally and believe it can lower hypo risk and expand access for people not currently on AID.
"At a minimum, we would expect that we can get type 2 indication for that mode of the algorithm." — Sean Saint (CEO)
Why withdraw 3D filing and FCL timing
Q (Jonathan Block · Stifel): Why withdraw the 3D filing instead of answering FDA questions, and is there timing for forced FCL approval?
A: They said they withdrew because they ran out of the FDA's 90-day review time and couldn't finish answering late questions; withdrawing and resubmitting is standard procedure, and that is why a Q4 clearance remains possible though next year is more likely. They have not provided timing for forced FCL approval yet.
"The simple fact is that, we got to the end of the 90-day review period, and some of these questions kind of came up near the end, and that's okay." — Sean Saint (CEO)
Sales force readiness before Mint launch
Q (Mathew Blackman · TD Cowen): What's the state of the sales force, how are reps ramping, and what is the plan to raise Mint awareness?
A: They said the sales force primarily calls on health care providers and they can get the word out to providers, which is the main goal before launch. They expanded the field team to reach providers quickly ahead of Mint; rep ramp slowed as expected but will help increase scripts and provider engagement for launch.
"The sales force, while they absolutely talk to users every day, primarily are calling on health care providers, right?" — Sean Saint (CEO)
Formulary process and 40% coverage reasons
Q (Stephanie ELGHAZI · BofA): How will Mint get on formulary and is the 40% coverage at launch accounting for that process?
A: They said the 40% launch coverage expectation is based on Mint being designated a patch pump (Medicare Part D), which makes reimbursement easier, and on existing relationships with major PBMs and plans from their iLet experience. They have prepared market access work and believe that supports achieving the stated coverage.
"Number one is that Mint is considered a patch pump for reimbursement purposes, meaning it is a Medicare Part D product, or at least that's the reimbursement designation." — Stephen Feider (CFO)
Conversion from iLet to Mint and churn
Q (Richard Newitter · Truist): How much of Mint's 2027 base might be converted existing iLet users, and any changes in churn or type 2 retention?
A: They would not give exact percentages but said many iLet users will prefer Mint and that early launch prioritization may push more conversions from iLet if capacity is constrained. They also said retention remains strong with no notable churn changes; type 2 retention is slightly better than type 1.
"I do think that many iLet users, for reasons I've communicated earlier, are going to prefer to wear Mint, for reasons I hope that are clear to you all." — Stephen Feider (CFO)
Market expansion versus share taking
Q (Stephanie ELGHAZI · BofA): With multiple patch and tubeless options next year, will Mint expand the market or take share, and what share capture do you expect?
A: They said they focus on designing the best product; both market expansion and share taking are possible and both are good outcomes. They did not give numeric share guidance but said Mint is built to be applicable to most users and they expect to improve outcomes by offering a product more people will use.
"When we think about that question, we think primarily about designing the right product and whether we take share or whether we expand the market, we do better either way, and we do that by designing a better product in both cases." — Sean Saint (CEO)